Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial.
Matthieu RoustitMarie-Camille ChaumaisClaire ChapuisAnne Gairard-DoryCaroline HadjadjSébastien ChanoineBenoît AllenetOlivier SitbonChristophe PisonPierrick Bedouchnull nullPublished in: International journal of clinical pharmacy (2020)
Background Pulmonary hypertension is a rare, chronic and life-threatening group of diseases. Recent advances in pulmonary hypertension management prolong survival and improve quality-of-life. However, highly complex drug therapy enhances the risk of drug-related problems. Objective To assess the impact of involving clinical pharmacists in the collaborative care of pulmonary hypertension patients. Setting Ten French University Hospital Pneumology departments, all members of the French Network for Pulmonary Hypertension. Methods This prospective multicenter randomized controlled trial included incident pulmonary hypertension patients who were followed-up for 18 months. Randomization using an adapted Zelen method allocated patients to collaborative care (n = 41) or usual care groups (n = 51). A collaborative care program involving clinical pharmacists was developed through a close partnership between with physicians, nurses and pharmacists. Besides usual care, the program includes regular one-to-one interviews between the pharmacist and the patient. These interviews had following objectives: to perform an exhaustive medication history review; to identify the patient' needs, knowledge and skills; to define educational objectives and to provide patients with relevant information when needed. Following each interview, a standardized report form containing the pharmacist's recommendations was provided to physicians and nurses and discussed collaboratively. An ancillary economic analysis was performed. Main outcome measure Number of drug-related problems and their outcomes. Results The number of drug-related problems was not significantly different between groups (1.6 ± 1.5 vs. 1.9 ± 2.4; p = 0.41). More problems were resolved in the collaborative care group than in the usual care group (86.5% vs. 66.7%, p = 0.01). Time to clinical worsening, therapeutic adherence, satisfaction or quality-of-life were not statistically different between groups. Collaborative care decreased costs of drug-related hospitalizations. Conclusion Including clinical pharmacists in the multidisciplinary care of hospitalized patients with pulmonary hypertension improved the outcome of drug-related problems and reduced the costs of related hospitalization. However, we observed no efficacy on medication errors, clinical outcomes or medication adherence. Clinical Trial Registration ClinicalTrials.gov Identifier NCT01038284.
Keyphrases
- quality improvement
- pulmonary hypertension
- healthcare
- palliative care
- patient safety
- mental health
- randomized controlled trial
- clinical trial
- end stage renal disease
- pulmonary artery
- affordable care act
- pulmonary arterial hypertension
- pain management
- newly diagnosed
- study protocol
- ejection fraction
- peritoneal dialysis
- adverse drug
- bone marrow
- type diabetes
- cardiovascular disease
- smoking cessation
- metabolic syndrome
- skeletal muscle
- health insurance
- cross sectional
- insulin resistance